<DOC>
	<DOCNO>NCT02714842</DOCNO>
	<brief_summary>This single-centre , open-label , randomised , three-arm crossover study fourth fix arm subset subject . Up 36 healthy male volunteer participate study . This study design correlate gastrointestinal transit behaviour delayed-release diclofenac sodium tablet pharmacokinetic ( PK ) absorption profile . The investigator look : 1 . The behaviour tablet ( , quickly break ) 2 . The gastric emptying time tablet ( leave stomach ) 3 . The gastrointestinal transit tablet ( long take travel gut ) 4 . Blood level drug ( diclofenac )</brief_summary>
	<brief_title>Delayed Release Diclofenac Sodium Formulation v Voltaren®</brief_title>
	<detailed_description />
	<mesh_term>Diclofenac</mesh_term>
	<criteria>Male Aged 18 55 year inclusive . Weight &amp; Body mass index ( BMI ) BMI 18.0 29.9 kg/m² , inclusive . Body weight ≥50 kg Understands willing , able likely comply study procedure restriction . Demonstrates understand study willingness participate evidence voluntary write informed consent ( sign date ) obtain trialrelated activity . ( Trialrelated activity procedure would perform normal management subject . ) Good general health ( opinion Investigator ) clinically significant relevant abnormality medical history physical examination . Current relevant previous history severe uncontrolled disease , opinion physician responsible , could affect study conduct laboratory assessment ( e.g. , renal , cardiovascular , hepatic , hematologic , endocrine , pulmonary , psychiatric , neurologic , cerebral disease ) . Current relevant previous history serious , severe unstable physical psychiatric illness , medical disorder may require treatment make subject unlikely fully complete study , condition present undue risk study medication procedure . A history current relevant previous non selflimiting gastrointestinal disorder particular , peptic ulcer disease and/or gastrointestinal bleeding . A history hypersensitivity aspirin NSAID . Suffering asthma require current treatment . Currently suffer disease know impact gastric emptying , e.g. , migraine , insulindependent diabetes mellitus . Laboratory screen result suggest abnormal liver and/or renal function . Subject screen QTc value great equal 450 msec ECG suitable QTc measurement ( e.g. , poorly define termination Twave ) . The ECG take screening must consider clinically significant Investigator/ study physician . Currently suffer bleed coagulation disorder . As result physical examination screen investigation , physician responsible considers volunteer unfit study . Subject take prescribed medication within 14 day prior first assessment visit , opinion physician responsible , interfere study procedure compromise safety . Subjects withdraw subsequent study day commence take prescribed medication study period , opinion physician responsible , interfere study procedure compromise safety . Subject take overthecounter ( OTC ) medication within 48 hour prior assessment visit . T This include use vitamin natural herbal remedy e.g. , St John 's Wort . Subjects take OTC medication may still enter study , opinion physician responsible , medication interfere study procedure compromise safety . The occasional use paracetamol pain relief ( within label dosage ) permit must take within 48 hour Assessment Visit . Recent history ( within last year ) alcohol substance abuse . Subject average weekly alcohol intake great 21 unit . 1 unit equivalent one 25 mL single measure whisky , third pint beer half standard ( 175 mL ) glass red wine . Subject positive urine drug abuse test screening . Note : At discretion Investigator , test may repeat . Subject positive breath alcohol test screening . Subject recently discontinue smoking ( le 3 month ) . Subject currently smoker user nicotinecontaining product . Subject history allergy study drug diclofenac sodium , component dosage form allergy , , opinion physician responsible , contraindicate participation . Has allergy content meal . Subject vegetarian . Subject claim lactose intolerant . Participation another clinical study ( inclusive final poststudy examination ) receipt investigational drug within 12 week screen visit . Previous participation study . Subject whose participation study result participation four study twelve month period . An employee sponsor , client study site member immediate family . Subjects participation study exceed limit total radiation exposure allow 12 month period ( 5 mSv ) , exceed 10 mSv three year period . Subjects intend father child 3 month follow study unwilling abstain sexual intercourse pregnant lactating woman . Subjects unwilling use condom/spermicide addition female partner use another form contraception IUD , diaphragm spermicide , oral contraceptive , injectable progesterone , subdermal implant tubal ligation woman could become pregnant time first assessment visit 3 month follow study . Subject donate blood experienced significant blood loss within 3 month screen throughout duration study . Difficulty access forearm vein cannulation blood sampling . Subject nonremovable metal object metal plate , screw etc . chest abdominal area .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>September 2016</verification_date>
</DOC>